Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
Automated microscopy and Spatial Proteomics
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Related topics
The chicken chorioallantoic membrane as a low-cost, high-throughput model for cancer imaging
Apr 4, 2024
Here, we assessed the chicken chorioallantoic membrane (CAM) as an alternative to mice for preclinical cancer imaging...
A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence
Apr 3, 2024
A thrombin-responsive and fixed-point cleaved Fu@pep-CLipo was developed for highly efficient and precise thrombolysis...
Webinar: Multimodal Assessment of Hypoxia in Tumors: From the Lab to the Clinic
Apr 2, 2024
25 April 2024, 4PM CET
This webinar will be of interest to multiple profiles in the community of biomedical...
Multiplexed tissue imaging using the Orion platform to reveal the Spatial Biology of Cancer
Mar 27, 2024
In this webinar Prof. Sandro Santagata, will reveal how Orion high-plex imaging and the use of this data, is valuable...
A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia
Mar 13, 2024
This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...
18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs
Mar 11, 2024
A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...
Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System
Mar 8, 2024
Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...
Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight
Feb 23, 2024
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Apr 1, 2020
This study identifies Notch1 as a therapeutic target in prostate cancer. Loss of NOTCH1 in aggressive prostate cancer cells decreases proliferation, invasion, and tumorsphere formation. Therapeutic inhibition of Notch1 activity with gamma secretase inhibitors RO4929097 or DAPT in prostate cancer cells further results in decreased proliferative abilities. Loss of NOTCH1 and treatment of immunocompromised mice bearing prostate cancer xenografts with RO4929097 display significantly impaired tumor growth. Loss of NOTCH1 additionally decreased metastatic potential of prostate cancer cells in invasion assays in vitro as well as in vivo experiments. Moreover, treatment with gamma secretase inhibitors or NOTCH1 gene deletion synergized with antiandrogen therapies, enzalutamide or abiraterone, to decrease the growth of prostate cancer cells. Combination of gamma secretase inhibitors with abiraterone significantly inhibited cell migration and invasion, while combination with enzalutamide reversed enzalutamide-induced migration and invasion. These collective findings suggest loss of NOTCH1 delays growth of CRPC and inhibits metastasis, and inhibition of Notch1 activation in conjunction with second-generation antiandrogen therapies could delay growth and progression of prostate cancer.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
More info at:
https://spectralinvivo.com/